10 likes | 146 Views
Table 2 Data for use of immune modifiers in the treatment of severe gut dysmotility syndromes including CIPO related to myenteric ganglionitis. Permission obtained from John Wiley & Sons Inc. De Giorgio, R. & Camilleri, M. Human enteric neuropathies: morphology and molecular pathology.
E N D
Table 2Data for use of immune modifiers in the treatment of severe gut dysmotility syndromes including CIPO related to myenteric ganglionitis Permission obtained from John Wiley & Sons Inc. De Giorgio, R. & Camilleri, M. Human enteric neuropathies: morphology and molecular pathology. Neurogastroenterol. Motil. 16, 515–531 (2004). Knowles, C. H. et al.(2013)New perspectives in the diagnosis and management of enteric neuropathies Nat. Rev. Gastroenterol. Hepatol.doi:10.1038/nrgastro.2013.18